GenSight Biologics

GenSight Biologics is a clinical-stage biotechnology company discovering and developing novel therapies for mitochondrial and neurodegenerative diseases of the eye and central nervous system. To address these therapeutic areas, the Company leverages its integrated development platform by combining a gene therapy-based approach with its core technology platforms of mitochondrial targeting sequence and optogenetics.

GenSight's initial focus has been on developing therapies for severe retinal diseases, with the goal of preserving or restoring vision in patients suffering from sight-threatening ophthalmic diseases.

Company Growth (employees)
Paris, FR
Size (employees)
31 (est)
GenSight Biologics was founded in 2011 and is headquartered in Paris, FR

GenSight Biologics Office Locations

GenSight Biologics has an office in Paris
Paris, FR (HQ)
74 Rue du Faubourg Saint-Antoine

GenSight Biologics Data and Metrics

GenSight Biologics Financial Metrics


Market capitalization (24-Jul-2017)

101.6 m

Closing share price (24-Jul-2017)

GenSight Biologics's current market capitalization is €101.6 m.

GenSight Biologics Market Value History

Traffic Overview of GenSight Biologics

GenSight Biologics News and Updates

This company is trying a radical approach to reverse a rare form of blindness

For those living with an inherited form of blindness that comes on suddenly, a one-time injection could be life-changing.  Leber's hereditary optic neuropathy (LHON) is a rare cause of blindness that comes on suddenly in young adults. It's a genetic disorder that is diagnos…

BRIEF-Gensight Biologics announces exercise of 88.9 pct of over-allotment option in IPO

* Gensight Biologics announces exercise of 88.9 pct of the over-allotment option in its IPO

GenSight Biologics Company Life and Culture

You may also be interested in